Bli medlem
Bli medlem

Du är här

2015-03-31

Nexstim Oyj: Nexstim Plc ("Nexstim" or "Company") Resolutions of the annual general meeting of shareholders

Helsinki, 31 March 2015, 12:00 pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to
improve rehabilitation for stroke patients with the use of non-invasive brain
stimulation, announces that the following resolutions were adopted at its
annual general meeting of shareholders held today on 31 March.

The annual general meeting of shareholders of Nexstim Plc adopted the
Company's financial statements, including the consolidated financial
statements for the year 2014, and discharged the members of the Board of
Directors and the Chief Executive Officer from liability.

Dividend and handling of loss

The general meeting decided that no dividend would be paid for the financial
year 1 January 2014 - 31 December 2014 and that the loss of the financial
year be added to the loss account.

Composition and remuneration of the Board of Directors

The general meeting resolved the number of the members of the Board of
Directors at seven. Olli Riikkala, Ken Charhut, Ekaterina Smirnyagina, Juha
Vapaavuori, Rene Kuijten, Juliet Thompson and Johan Christenson were elected
to the Board; Olli Riikkala was elected as the chair and Johan Christenson as
the deputy chair.

The new Board member, Juliet Thompson, has spent approximately 20 years
working as an investment banker and strategic advisor to healthcare companies
in Europe. She he has built a strong track record of advising companies on
corporate strategy, equity and debt fundraisings and international M&A. She
is a Chartered Accountant ACA; Chartered Institute for Securities and
Investment (ASCI); Bsc Economics (Bristol University). Her experience
includes roles at Oriel Securities, Nomura Code Securities, WestLB Panmure,
ICI PLC, Deloitte and Touche and HM Treasury.

The remuneration of the members of the Board of Directors was resolved as
follows: €45,000 for the chair of the board, €36,000 for the members of the
board domiciled in the USA, €18,000 for the members domiciled in Finland, and
€27,000 for the members domiciled in Europe, outside Finland. The general
meeting recommended that the members of the board invest half of the
above-mentioned remuneration in the Company's shares.

Further, the general meeting resolved that the members of the board committees
domiciled in Finland be paid as follows for each committee meeting at which
they are present: €1,000 for the chair of the committee and €500 for the
other members of the committee. The members of the board committees domiciled
in the USA will be paid as follows for each committee meeting at which they
are present: €2,000 for the chair of the committee and €1,000 for the other
members of the committee. The members of the board committees domiciled in
Europe but outside Finland, will be paid as follows for each committee
meeting at which they are present: €1,500 for the chair of the committee and
€750 for the other members of the committee.

It was decided that reasonable travel expenses of the ordinary members of the
board be compensated against receipts.

Election of the auditor and auditor's fee

PricewaterhouseCoopers Oy, an auditing firm approved by the Finnish Chambers
of Commerce, was re-elected as the auditor with Martin Grandell acting as the
auditor-in-charge. The auditor will be paid a reasonable fee in accordance
with an invoice approved by the Company.

Proposal of the Board of Directors for authorising the Board of Directors to
decide on the repurchase of the company's own shares

The general meeting decided that the Board of Directors be authorised to
decide on the repurchase of the Company's own shares as follows:

The amount of own shares to be repurchased will not exceed 1,069,613 shares,
which corresponds to approximately 15 per cent of all of the shares in the
Company. For the sake of clarity, it was noted, however, that the Company
together with its subsidiaries cannot simultaneously possess more than 10 per
cent of its registered amount of shares.

The Board of Directors will decide on how shares will be repurchased. Shares
can be repurchased using, inter alia, derivatives. Own shares can also be
repurchased otherwise than in proportion to the shareholdings of the
shareholders (directed repurchase). The minimum price of the shares
repurchased is the lowest listed market price of the share during the period
of authorisation and, correspondingly, the maximum price is the highest
listed market price of the share during the period of authorisation. If the
Board of Directors uses the authorisation granted to it by the general
meeting, it will follow the guidelines for the repurchase of a company's own
shares of the Helsinki Stock Exchange, as applicable.

Own shares can be repurchased, inter alia, to limit the dilutive effects of
share issues carried out in connection with possible acquisitions, to develop
the Company's capital structure, to be transferred in connection with
possible acquisitions, to be used in the Company's incentive arrangements or
to be cancelled, provided that the repurchase is in the interest of the
Company and its shareholders.

The authorisation is effective for 18 months from the resolution of the
general meeting.

Authorising the Board of Directors to decide on the issuance of shares as well
as the issuance of special rights entitling to shares

The general meeting authorised the Board of Directors to decide on the
issuance of shares as well as the issuance of special rights entitling to
shares referred to in chapter 10 of the Finnish Companies Act as follows:

Shares potentially issued by virtue of the special rights entitling to shares
are new shares or shares held by the Company. The maximum amount of shares
potentially issued by virtue of the special rights entitling to shares is
1,069,613 shares, which corresponds to approximately 15 per cent of all of
the shares in the Company. Shares or special rights entitling to shares can
be issued in one or more parts.

The Board of Directors is authorised to decide on all the conditions of the
issuance of shares and special rights entitling to shares. The issuance of
shares and special rights entitling to shares may be carried out in deviation
from the shareholders' pre-emptive rights by way of a directed issue,
provided that there is a weighty financial reason for doing so. The
authorisation may also be used for incentive arrangements and to pay
remuneration to the board members.

The proposed authorisation annuls the authorisations resolved and registered
during the previous general meetings regarding the issuance of shares and
special rights entitling to shares, as well as to the transfer of the
Company's own shares.

The authorisation is valid for three (3) years from the resolution of the
general meeting.

Board's proposal for an amendment of the articles of association

The general meeting decided that section 4 of the articles of association will
be amended as follows:

"Section 4. Representation rights

The right to represent the Company is vested in the chair of the Board of
Directors and the Chief Executive Officer, each one alone, and two jointly
acting members of the board of directors, as well as the persons authorised
by the Board of Directors to represent the Company, two of them acting
jointly, or each such person acting together with the chair of the Board of
Directors, a member of the Board of Directors or the Chief Executive Officer.

The Board of Directors resolves on granting representation rights and
procurations."

Minutes of the general meeting

The minutes of the general meeting will be published on, or by, 14 April 2015,
on Nexstim's website.

NEXSTIM PLC
Janne Huhtala, CEO

Further information is available on the website
www.nexstim.comor by contacting:

Nexstim

+358 (0)40 8615046
Janne Huhtala, CEO

janne.huhtala@nexstim.com

UB Capital Oy
(certified adviser)
+358 (0)9 2538 0225

Consilium Strategic Communications

+44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan
nexstim@consilium-comms.com

About Nexstim Plc

Nexstim is a medical technology company founded in 2000 in Finland aiming to
improve rehabilitation for stroke patients. Nexstim has pioneered its
technology as a diagnostic tool for brain surgery with its Navigated Brain
Stimulation (NBS) system. It is the first and only FDA cleared and CE-marked
system based on the navigated transcranial magnetic stimulation (nTMS) for
pre-surgical mapping of the speech and motor cortices of the brain. Based on
the same technology platform, the company has developed a device called
Navigated Brain Therapy (NBT®) for use in the rehabilitation of stroke
patients. During the first half of 2014, Nexstim started a two-year Phase III
key study in 12 locations in the USA with the aim of demonstrating the
efficiency of the NBT® equipment and receiving FDA clearance to market said
equipment for post-acute rehabilitation of stroke patients in the USA.
Nexstim shares have been listed on Nasdaq First North Finland and Nasdaq
First North Sweden. Further information is available on the website
www.nexstim.com.

Nexstim AGM resolutions
http://hugin.info/138152/R/1907634/679579.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire

HUG#1907634

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.